Subscribe

Spotlight -

This Year In Medicine 2025

Fewer Severe ISM Symptoms After 4 Years of Avapritinib: Thanai Pongdee, MD

Thanai Pongdee, MD, discusses 4-year PIONEER symptom data with avapritinib, skin-symptom findings, and the PANORAMA-US study in ISM at ACAAI 2026.

Fewer Severe ISM Symptoms After 4 Years of Avapritinib: Thanai Pongdee, MD

Episodes

Specialty:

All

Year:

All

Fewer Severe ISM Symptoms After 4 Years of Avapritinib: Thanai Pongdee, MD

EP. 1: Fewer Severe ISM Symptoms After 4 Years of Avapritinib: Thanai Pongdee, MD

ByThanai Pongdee, MD

November 13th 2026

Thanai Pongdee, MD, discusses 4-year PIONEER symptom data with avapritinib, skin-symptom findings, and the PANORAMA-US study in ISM at ACAAI 2026.

Trending on HCPLive

Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial

FMXIN002 Double Dose Delivers Faster Epinephrine Exposure Than Autoinjector

Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2D